Overall, for women with RA who received ETA or ADA, both TNF-α-blocking agents led to a significant decrease in serum levels of COMP (873.52 ± 334.26 ng/mL to 733.56 ± 317.77 ng/mL and 928.46 ± 349.58 ng/mL to 734.30 ± 188.33 ng/mL, respectively) (both p < 0.05; Figure 4d). Here, ADA is linked to rheumatoid arthritis.